Latest Blogs

Mar 14, 2024
When everyone is aligned with values and purpose in our societies and workplaces, we create spaces that put the well-being of all humans at the center, according to Prof. Sabe Sabesan, Anoj Sabesan, and Prof. Lynden Roberts.
Feb 27, 2024
Dr. Faye Lim describes her experience as a faculty member on multidisciplinary team management at events in Sarawak, Malaysia.
Feb 27, 2024
Dr. Ellen Zhang's original poem was composed in honor of her grandmother and her patients.
Feb 15, 2024
This year’s recipients were indeed distinguished leaders in their fields and have dedicated their careers to improve diagnosis, outcomes, and quality of life as well advancing personalized therapy for patients. 
Subscribe to this column

ASCO Commentary

ASCO Commentary provides an interactive platform for ASCO’s organizational leadership and senior staff to connect directly to ASCO’s membership and the wider oncology community.

Jan 29, 2024
At the midpoint of her term as 2023-2024 ASCO president, Dr. Lynn M. Schuchter highlights key points of progress from 2023 and looks toward a busy year ahead.
Feb 02, 2023
As we acknowledge World Cancer Day on February 4, Dr. Julie R. Gralow shares how ASCO is engaging members in different regions of the world, "uniting our voices and taking action," through its regional councils.
Nov 10, 2022
ASCO president Dr. Eric P. Winer and Nominating Committee chair Dr. Beverly S. Mitchell call upon all eligible voters to make their voices heard in the ASCO election.
Nov 03, 2021
ASCO president Dr. Everett E. Vokes and Nominating Committee chair Dr. Sharon H. Giordano have a call to action for all voting-eligible members.
Feb 21, 2018
Dr. Richard L. Schilsky describes ASCO's Targeted Agent and Profiling Utilization Registry (TAPUR) Study and similar independent studies worldwide.
Oct 28, 2016
Dr. Richard L. Schilsky outlines the Society's Target Agent and Profiling Utilization Registry (TAPUR) Study and similar international protocols. A global data sharing platform could greatly accelerate our ability to learn about new uses for currently approved targeted anticancer drugs.

Pages